Scholtz & Company’s Vericel Corp VCEL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.29M Buy
+51,409
New +$1.85M 1.14% 29
2025
Q3
Sell
-50,573
Closed -$2.15M 54
2025
Q2
$2.15M Buy
50,573
+454
+0.9% +$18.9K 0.94% 35
2025
Q1
$2.24M Buy
50,119
+2,459
+5% +$132K 1.11% 30
2024
Q4
$2.62M Buy
47,660
+4,562
+11% +$231K 1.25% 25
2024
Q3
$1.82M Buy
43,098
+13,525
+46% +$644K 0.86% 32
2024
Q2
$1.36M Buy
+29,573
New +$1.39M 0.58% 32

Other funds holding VCEL

Scholtz & Company's VCEL Position: Q2 2026 in Review

Scholtz & Company opened a new position in Vericel Corp (VCEL) in Q2 2026: 51,409 shares worth $2.29M. The stake represents 1.14% of the portfolio and ranks #29 among its holdings. This is a return to the name: Scholtz & Company previously reported a position in VCEL as recently as Q2 2025.

Scholtz & Company first reported a position in VCEL in Q2 2024 and has held it in 6 quarters since. The position peaked at $2.62M in Q4 2024. 319 funds tracked by Wall St. Rank hold VCEL as of Q2 2026.

  • Scholtz & Company held 51,409 shares of Vericel Corp worth $2.29M as of Q2 2026.
  • Vericel Corp was a new Scholtz & Company position in Q2 2026.
  • Vericel Corp made up 1.14% of Scholtz & Company's portfolio in Q2 2026, its #29 holding.
  • Scholtz & Company first reported a position in Vericel Corp in Q2 2024 and has held it in 6 quarters since.
  • Scholtz & Company's Vericel Corp position peaked at $2.62M in Q4 2024.
  • 319 funds tracked by Wall St. Rank held Vericel Corp as of Q2 2026.

Based on Scholtz & Company's 13F filing for Q2 2026, filed 11 Aug 2026.